New developments in the treatment of multiple myeloma – clinical utility of daratumumab
Cian McEllistrim,1 Janusz Krawczyk,1 Michael E O’Dwyer1,2 1Department of Hematology, University Hospital Galway, 2Apoptosis Research Centre, Biomedical Sciences, National University of Ireland Galway, Galway, Ireland Abstract: Multiple myeloma is a clonal disorder of plasma cells that is c...
Guardado en:
Autores principales: | McEllistrim C, Krawczyk J, O'Dwyer ME |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c229836b281a48faa9fdf43a7f7fa2af |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
por: Edvan de Queiroz Crusoé, et al.
Publicado: (2021) -
Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
por: Karina E. Zatolochina, et al.
Publicado: (2021) -
Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Shebli ATRASH, et al.
Publicado: (2021) -
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
por: Elodie Duray, et al.
Publicado: (2021) -
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
por: Maarten R. Seefat, et al.
Publicado: (2021)